Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boehringer, Forma Strike Discovery Deal In Oncology

This article was originally published in The Pink Sheet Daily

Executive Summary

The German pharma pays $65 million upfront in a deal with high-ceilinged milestones, in an ambitious effort to discover cancer drugs that affect protein-protein interactions.

Advertisement

Related Content

With Celgene Deal, Forma Makes First Foray Into Clinical Development
How To Place Bets On Early Oncology Assets
Start-Up Quarterly Statistics, Q1 2012
Janssen Teams Up With Forma On Tumor Metabolism
Deals Of The Week: Forma/Boehringer Ingelheim, Biogen/Isis, Alnylam/Arrowhead
Forma To Play To Its Strengths WIth Genentech Deal
Genentech Licenses A Cancer Metabolism Program From Forma, With Option To Buy
The Allure Of High-Hanging Fruit: Why VCs and Biotech Execs See Value In Difficult Drug Targets
Lilly, Novartis Help Forma Therapeutics Raise $25 Million To Expand R&D In Asia

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS073219

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel